Skip to main content
Journal cover image

Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved.

Publication ,  Journal Article
Wiehe, K; Easterhoff, D; Luo, K; Nicely, NI; Bradley, T; Jaeger, FH; Dennison, SM; Zhang, R; Lloyd, KE; Stolarchuk, C; Parks, R; Scearce, RM ...
Published in: Immunity
December 18, 2014

In HIV-1, the ability to mount antibody responses to conserved, neutralizing epitopes is critical for protection. Here we have studied the light chain usage of human and rhesus macaque antibodies targeted to a dominant region of the HIV-1 envelope second variable (V2) region involving lysine (K) 169, the site of immune pressure in the RV144 vaccine efficacy trial. We found that humans and rhesus macaques used orthologous lambda variable gene segments encoding a glutamic acid-aspartic acid (ED) motif for K169 recognition. Structure determination of an unmutated ancestor antibody demonstrated that the V2 binding site was preconfigured for ED motif-mediated recognition prior to maturation. Thus, light chain usage for recognition of the site of immune pressure in the RV144 trial is highly conserved across species. These data indicate that the HIV-1 K169-recognizing ED motif has persisted over the diversification between rhesus macaques and humans, suggesting an evolutionary advantage of this antibody recognition mode.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Immunity

DOI

EISSN

1097-4180

Publication Date

December 18, 2014

Volume

41

Issue

6

Start / End Page

909 / 918

Location

United States

Related Subject Headings

  • Protein Engineering
  • Protein Binding
  • Phylogeny
  • Mutation
  • Molecular Sequence Data
  • Macaca mulatta
  • Immunology
  • Immunoglobulin Light Chains
  • Humans
  • HIV-1
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wiehe, K., Easterhoff, D., Luo, K., Nicely, N. I., Bradley, T., Jaeger, F. H., … Haynes, B. F. (2014). Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. Immunity, 41(6), 909–918. https://doi.org/10.1016/j.immuni.2014.11.014
Wiehe, Kevin, David Easterhoff, Kan Luo, Nathan I. Nicely, Todd Bradley, Frederick H. Jaeger, S Moses Dennison, et al. “Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved.Immunity 41, no. 6 (December 18, 2014): 909–18. https://doi.org/10.1016/j.immuni.2014.11.014.
Wiehe K, Easterhoff D, Luo K, Nicely NI, Bradley T, Jaeger FH, et al. Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. Immunity. 2014 Dec 18;41(6):909–18.
Wiehe, Kevin, et al. “Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved.Immunity, vol. 41, no. 6, Dec. 2014, pp. 909–18. Pubmed, doi:10.1016/j.immuni.2014.11.014.
Wiehe K, Easterhoff D, Luo K, Nicely NI, Bradley T, Jaeger FH, Dennison SM, Zhang R, Lloyd KE, Stolarchuk C, Parks R, Sutherland LL, Scearce RM, Morris L, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Sinangil F, Phogat S, Michael NL, Kim JH, Kelsoe G, Montefiori DC, Tomaras GD, Bonsignori M, Santra S, Kepler TB, Alam SM, Moody MA, Liao H-X, Haynes BF. Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. Immunity. 2014 Dec 18;41(6):909–918.
Journal cover image

Published In

Immunity

DOI

EISSN

1097-4180

Publication Date

December 18, 2014

Volume

41

Issue

6

Start / End Page

909 / 918

Location

United States

Related Subject Headings

  • Protein Engineering
  • Protein Binding
  • Phylogeny
  • Mutation
  • Molecular Sequence Data
  • Macaca mulatta
  • Immunology
  • Immunoglobulin Light Chains
  • Humans
  • HIV-1